Stockscreener 앱 받기
5.915
1.49%
0.065
전일 마감가:
$5.85
열려 있는:
$5.91
하루 거래량:
35,456
Relative Volume:
0.74
시가총액:
$212.89M
수익:
-
순이익/손실:
$-25.50M
주가수익비율:
-7.6818
EPS:
-0.77
순현금흐름:
$-30.10M
1주 성능:
+3.26%
1개월 성능:
+10.15%
6개월 성능:
+102.98%
1년 성능:
+124.05%
1일 변동 폭
$5.71
$5.925
1주일 범위
$5.59
$6.2289
52주 변동 폭
$2.20
$7.19
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
EPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
5.92 | 295.99M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.47 | 103.40B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.70 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.85 | 59.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
792.50 | 48.96B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
341.99 | 37.77B | 4.56B | -176.77M | 225.30M | -1.7177 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-26 | 개시 | H.C. Wainwright | Buy |
| 2025-06-16 | 개시 | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | 개시 | Craig Hallum | Buy |
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc 주식(EPRX)의 최신 뉴스
Quantitative breakdown of Eupraxia Pharmaceuticals Inc. recent movePortfolio Risk Summary & Weekly Breakout Watchlists - newser.com
Will Eupraxia Pharmaceuticals Inc. stock outperform Nasdaq indexEarnings Beat & High Accuracy Swing Trade Signals - newser.com
Is Eupraxia Pharmaceuticals Inc. (X43) stock considered safe havenShare Buyback & Verified Momentum Stock Watchlist - newser.com
(EPRX.WT.A) Trading Report (EPRX.WT.A:CA) - news.stocktradersdaily.com
Why Eupraxia Pharmaceuticals Inc. is moving today2025 Bull vs Bear & Verified Entry Point Detection - newser.com
Historical volatility pattern of Eupraxia Pharmaceuticals Inc. visualizedJuly 2025 Outlook & Low Risk High Win Rate Picks - newser.com
Measuring Eupraxia Pharmaceuticals Inc.’s beta against major indices2025 Trading Recap & Daily Growth Stock Investment Tips - newser.com
Technical analysis overview for Eupraxia Pharmaceuticals Inc. stock2025 Analyst Calls & Safe Entry Point Identification - newser.com
(EPRX) Technical Pivots with Risk Controls (EPRX:CA) - news.stocktradersdaily.com
This small Canadian pharma stock is undervalued, analyst says - Cantech Letter
Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion - MSN
Can Eupraxia Pharmaceuticals Inc. stock double in next 5 yearsJuly 2025 Institutional & Safe Capital Investment Plans - newser.com
Why Eupraxia Pharmaceuticals Inc. (X43) stock could outperform next year2025 Price Targets & Entry Point Confirmation Alerts - newser.com
Will Eupraxia Pharmaceuticals Inc. (X43) stock beat Nasdaq index returnsLayoff News & Real-Time Volume Surge Alerts - newser.com
What’s next for Eupraxia Pharmaceuticals Inc. stock price2025 Fundamental Recap & Weekly High Momentum Picks - newser.com
Trend Tracker for (EPRX) (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering - MSN
Can Eupraxia Pharmaceuticals Inc. (X43) stock attract analyst upgradesQuarterly Profit Review & Community Verified Watchlist Alerts - newser.com
Eupraxia Reports Encouraging Safety And Efficacy Data From Eosinophilic Esophagitis Study - Benzinga
Eupraxia Pharmaceuticals stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
Eupraxia Pharmaceuticals stock maintains Overweight rating at Cantor Fitzgerald - Investing.com India
Eupraxia Pharmaceuticals Inc X43 Stock Analysis and ForecastStock Market Trends & Start Small. End Wealthy. - earlytimes.in
Eupraxia Pharmaceuticals Announces Positive Data from - GlobeNewswire
Will Supply Chain Issues Impact Ethos Limiteds PerformanceCash Flow Trends & Big Data Market Reports - earlytimes.in
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs - GlobeNewswire
Eupraxia Pharmaceuticals announces positive data from highest-dose cohort in the ongoing resolve trial in Eosinophilic Esophagitis - TradingView
Breakthrough EoE Treatment Success: Eupraxia's EP-104GI Shows Best-in-Class Results at 8mg Dose Level - Stock Titan
Eupraxia Pharmaceuticals Inc (EPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.43%
1.15%
자본화:
|
볼륨(24시간):